AbbVie lifts annual profit forecast on strong demand for newer immunology drugs

AbbVie raised its 2025 profit forecast after exceeding second-quarter earnings estimates, driven by robust sales of its newer immunology drugs Skyrizi ($4.42B) and Rinvoq ($2.03B). This strong performance is successfully offsetting the anticipated sales decline of its former blockbuster Humira ($1.18B), which faces increasing biosimilar competition. The company now projects adjusted annual EPS between $11.88 and $12.08, underscoring its strategic transition and continued inorganic growth efforts, including potential acquisition talks for Gilgamesh Pharmaceuticals.

Analysis

AbbVie has demonstrated a successful strategic pivot, reporting a strong second quarter and raising its full-year 2025 profit guidance. The company posted an adjusted EPS of $2.97, surpassing estimates of $2.88, and subsequently increased its annual profit forecast to a range of $11.88 to $12.08 per share. This positive revision is underpinned by the robust sales performance of its newer immunology drugs, Skyrizi and Rinvoq, which generated $4.42 billion and $2.03 billion in quarterly sales, respectively, both beating analyst expectations. This growth is effectively compensating for the anticipated decline of Humira, which saw sales fall to $1.18 billion, significantly missing the $1.45 billion estimate as it faces biosimilar competition. AbbVie's strategy also leans heavily on inorganic growth, having spent over $20 billion on acquisitions since 2023 and reportedly being in talks for a $1 billion deal for Gilgamesh Pharmaceuticals. However, a notable headwind has emerged in the form of a 15% U.S. tariff on EU-produced pharmaceuticals, which could impact margins for products like Botox, manufactured in its significant Irish facilities.

Key Decisions for Investors

• The demonstrated outperformance of Skyrizi and Rinvoq validates AbbVie's post-Humira growth strategy, suggesting investors can view the ongoing transition with increased confidence.
• Monitor the company's M&A pipeline, including the potential acquisition of Gilgamesh Pharmaceuticals, as continued deal-making is a core component of its strategy to backfill revenue and drive future growth.
• Investors should quantify the potential margin impact from the new 15% U.S. tariff on EU-produced drugs, particularly concerning products like Botox manufactured in Ireland, as this represents a key risk to future profitability.